REG1VN0126.HE Revenio Group Oyj
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is REG1VN0126.HE undervalued?
Graham numberThe Graham number of Revenio Group Oyj cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revenio Group Oyj fundamental analysis
No fundamental analysis for Revenio Group Oyj yet.
Revenio Group Oyj stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or eme…
Full company profileFinancial statements of Revenio Group Oyj are not available yet.
Revenio Group Oyj dividends
Revenio Group Oyj has not paid dividends in the last 3 fiscal years.
Who owns Revenio Group Oyj
Ownership data of Revenio Group Oyj is not available yet.
Revenio Group Oyj company profile
- Company name
- Revenio Group Oyj
- Ticker
- REG1VN0126.HE
- ISIN
- FI4000614938
- Exchange
- Helsinki Exchange
- Sector
- -
- Industry
- -
- Employees
- 765
- Fiscal year end
- December
- Address
- Härkähaankuja 7, Vantaa, Finland, 01730
- Phone
- 358 9 8775 1150
- Website
- reveniogroup.fi
About Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Revenio Group Oyj management
6- Mr. Jouni Toijala B.Sc., M.B.A.President & CEO · born 1968
- Mr. Jukka Kainulainen M.Sc.Chief Financial Officer · born 1982
- Mr. Ari IsomäkiVice President of Operations · born 1966
- Mr. John FloydVice President of Sales · born 1970
- Ms. Hanna VuornosVice President of People & Culture · born 1978
- Mr. Umberto BargiggiaVice President of International Sales · born 1982